Biotech archive
Every Biotech story, newest first. 88 in this archive.
Oct 12, 2026
Immorta Bio Prepares AI Designed SenoMune Peptide for 2026 Clinical Entry
On 12 October 2026 Immorta Bio said preclinical work on SenoMune 0257, a nine amino acid senolytic immunotherapy discovered with AI, is complete ahead of planned human studies.
Oct 11, 2026
Insitro Opens Lilly TuneLab In Vivo PK Models to External Biotech Teams
On 6 October 2026 insitro said Lilly TuneLab now offers biotech users the in vivo pharmacokinetic models the partners trained on decades of Lilly preclinical measurements.
Oct 10, 2026
Transcripta and Synfini Nominate an MSH3 Lead for Huntington in Weeks Not Months
Transcripta Bio and Synfini reported a validated quality lead against MSH3, a driver of somatic repeat expansion in Huntington disease, compressing discovery timelines with linked AI chemistry foundries.
Oct 9, 2026
GSK Adopts Chai Discovery Models After Internal Wet Lab Checks on De Novo Designs
GSK signed to use Chai Discovery protein design models after internal testing found binders across a diverse target panel, adding another Big Pharma validation step for generative antibody design.
Oct 8, 2026
PacBio and TychoBio Will Train RNA Models on 10000 HiFi Samples
PacBio and TychoBio announced a collaboration on 6 October 2026 to generate full length RNA data from more than 10000 samples to train models for steric blocking antisense and future siRNA design.
Oct 6, 2026
XtalPi Launches Kodexia Closed Loop siRNA Platform With Six Programs
XtalPi debuted Kodexia, combining generative AI, first principles RNA modeling, and automated labs for siRNA discovery, while advancing six internal therapeutic programs including IgA nephropathy.
Oct 5, 2026
Iambic Files IND for AI Designed Brain Penetrant KIF18A Inhibitor IAM217
Iambic Therapeutics submitted an FDA IND on 5 October 2026 for IAM217, its second wholly owned AI discovered oncology candidate targeting KIF18A with reported brain penetration and strong preclinical intracranial tumor regression.
Oct 4, 2026
Talus Bio Ptarmigan 1 Opens Structure Free Proteome Wide Binding Predictions
Talus Bio released Ptarmigan 1 on 1 October 2026, a public portal model that predicts small molecule binding across the human proteome without 3D structures, targeting disordered proteins long considered undruggable.
Oct 3, 2026
Xaira X Design Generated a Cancer Antibody Lead in Seven Weeks
Xaira Therapeutics disclosed its X Design model produced progressable antibody leads for two pipeline targets, including a de novo cancer candidate built in seven weeks and a difficult GPCR program.
Oct 2, 2026
Hansa Biopharma Deploys Cradle AI Across Autoimmune Discovery Pipeline
Hansa Biopharma will use Cradle's end to end protein engineering platform across autoimmune programs, joining a wave of October 2026 deals that move AI design from pilots into named pipeline stages.
Oct 1, 2026
Profluent Will Design Enzyme Therapies With BioMarin Using AI Models
Profluent and BioMarin announced on 30 September 2026 a collaboration to generate and optimize enzyme replacement candidates using Profluent protein language models.
Sep 30, 2026
Microsoft Quine Prioritized Tumor State Shifts and Validated Them in Wet Lab
Microsoft Research unveiled Quine on 29 September 2026, a multimodal biology harness that ranked compounds for tumor state transitions and validated top picks with Broad Institute collaborators over a weekend.
Sep 27, 2026
Roche Pays Atavistik $70 Million Upfront for Allosteric CVRM Discovery
Atavistik Bio will use its AMPS metabolite protein screening platform to discover allosteric small molecules for cardiovascular, renal, and metabolic targets under a Roche collaboration worth up to $1.9 billion in milestones.
Sep 26, 2026
Novo Nordisk Will Test Claude Science Inside Drug Discovery Workflows
Novo Nordisk and Anthropic announced on 16 September 2026 a collaboration to apply Claude Science and frontier models to biological reasoning tasks in R&D plus AI driven software development.
Sep 25, 2026
AbbVie Partners With Iambic on AI Small Molecule Discovery
AbbVie and Iambic announced a multi year collaboration on 21 September 2026 to apply Iambic's Enchant v3 AI platform across immunology, neuroscience, and oncology small molecule programs.
Sep 24, 2026
Earendil Labs Signs Genentech Bispecific Deal Worth Up to $1.5 Billion
Earendil Labs announced a Genentech collaboration on 24 September 2026 to discover bispecific cancer antibodies using generative protein engineering, extending AI biologics deal flow after major enzyme discovery headlines.
Sep 23, 2026
Anthropic ART Enzyme Find Shows AI Can Flag Biology Leads Not Yet Tools
Anthropic reports Claude agents found the ART enzyme system after searching 1.9 billion protein clusters, but the preprint says reverse transcriptase activity remains unproven.
Sep 22, 2026
Four Pharma Giants Begin Federated Training on Binding Affinity Models
AbbVie, AstraZeneca, Bristol Myers Squibb, and Johnson & Johnson will jointly train AISB Bind through Apheris without sharing raw compound libraries.
Sep 21, 2026
AbbVie Bets Enchant v3 Multimodal AI Across Three Therapeutic Areas
AbbVie and Iambic announced a multi year deal on 21 September to apply the Enchant v3 transformer, trained on more than 6,000 molecular properties, across immunology, neuroscience, and oncology discovery.
Sep 20, 2026
Mithrl Opens Mithrl 1 Early Access With Biomedical World Model Inside Customer Environments
Mithrl launches Mithrl 1 early access on 21 September 2026, pairing a validated biomedical world model with agentic routing inside each biopharma team's own environment.